Aspira Womens Health Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aspira Women’s Health Inc. | |
| Date: March 29, 2024 | /s/ Nicole Sandford |
|---|---|
| Nicole SandfordPresident and Chief Executive Officer (Principal Executive Officer) | |
| Date: March 29, 2024 | /s/ Torsten Hombeck |
| Torsten HombeckChief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
POWER OF ATTORNEY
Each of the undersigned officers and directors of Aspira Women’s Health Inc., hereby constitutes and appoints Nicole Sandford and
Torsten Hombeck, and each or any of them, as their true and lawful attorney-in-fact and agent, for them and in their name, place and
stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related
documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power
and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes
as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney
shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Nicole SandfordNicole Sandford | President and Chief Executive Officer(Principal Executive Officer) and Director | March 29 2024 |
| /s/ Torsten HombeckTorsten Hombeck | Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) | March 29 2024 |
| /s/ Jannie Herchuk | Chair of the Board of Directors | March 29 2024 |
| Jannie Herchuk | ||
| /s/ Stefanie Cavanaugh | Director | March 29 2024 |
| Stefanie Cavanaugh | ||
| /s/ Celeste Fralick | Director | March 29 2024 |
| Celeste Fralick | ||
| /s/ Ellen O’Connor-Vos | Director | March 29 2024 |
| Ellen O’Connor-Vos | ||
| /s/ Winfred Parnell | Director | March 29 2024 |
| Winfred Parnell | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.